Genomic variants in polycystic ovary syndrome

Ehrmann, 2005, Polycystic ovary syndrome, N Engl J Med, 352, 1223, 10.1056/NEJMra041536 Dunaif, 1997, Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis, Endocr Rev, 18, 774, 10.1210/er.18.6.774 Cooper, 1968, Hereditary factors in the Stein-Leventhal syndrome, Am J Obstet Gynecol, 100, 371, 10.1016/S0002-9378(15)33704-2 Givens, 1988, Familial polycystic ovarian disease, Endocrinol Metab Clin North Am, 17, 771, 10.1016/S0889-8529(18)30409-2 Legro, 2002, Insulin resistance in the sisters of women with polycystic ovary syndrome: association with hyperandrogenemia rather than menstrual irregularity, J Clin Endocrinol Metab, 87, 2128, 10.1210/jc.87.5.2128 Yildiz, 2003, Glucose intolerance, insulin resistance, and hyperandrogenemia in first degree relatives of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 2031, 10.1210/jc.2002-021499 Kaushal, 2004, Insulin resistance and endothelial dysfunction in the brothers of Indian subcontinent Asian women with polycystic ovaries, Clin Endocrinol (Oxf), 60, 322, 10.1111/j.1365-2265.2004.01981.x Escobar-Morreale, 2005, The molecular-genetic basis of functional hyperandrogenism and the polycystic ovary syndrome, Endocr Rev, 26, 251, 10.1210/er.2004-0004 Ordovas, 2003, Cardiovascular disease genetics: a long and winding road, Curr Opin Lipidol, 14, 47, 10.1097/00041433-200302000-00009 Cooper, 2003, Gene-environment interactions and the etiology of common complex disease, Ann Intern Med, 139, 437, 10.7326/0003-4819-139-5_Part_2-200309021-00011 Frishman, 1998, Biologic markers as predictors of cardiovascular disease, Am J Med, 104, 18S, 10.1016/S0002-9343(98)00184-3 Fernandez-Real, 2003, Insulin resistance and chronic cardiovascular inflammatory syndrome, Endocr Rev, 24, 278, 10.1210/er.2002-0010 Kelly, 2001, Low grade chronic inflammation in women with polycystic ovarian syndrome, J Clin Endocrinol Metab, 86, 2453, 10.1210/jc.86.6.2453 Boulman, 2004, Increased C-reactive protein levels in the polycystic ovary syndrome: a marker of cardiovascular disease, J Clin Endocrinol Metab, 89, 2160, 10.1210/jc.2003-031096 Bastard, 2000, Elevated levels of interleukin 6 are reduced in serum and subcutaneous adipose tissue of obese women after weight loss, J Clin Endocrinol Metab, 85, 3338, 10.1210/jc.85.9.3338 Escobar-Morreale, 2001, TNF-α and hyperandrogenism: a clinical, biochemical and molecular genetic study, J Clin Endocrinol Metab, 86, 3761, 10.1210/jc.86.8.3761 Villuendas, 2002, The −597 G/A and −174 G/C polymorphisms in the promoter of the interleukin 6 gene (IL6) are associated with hyperandrogenism, J Clin Endocrinol Metab, 87, 1134, 10.1210/jc.87.3.1134 Peral, 2002, The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism, J Clin Endocrinol Metab, 87, 3977, 10.1210/jc.87.8.3977 Escobar-Morreale, 2003, Association of polymorphisms in the Interleukin 6 receptor complex with obesity and hyperandrogenism, Obes Res, 11, 987, 10.1038/oby.2003.136 Escobar-Morreale, 2003, Obesity, and not insulin resistance, is the major determinant of serum inflammatory cardiovascular risk markers in pre-menopausal women, Diabetologia, 46, 625, 10.1007/s00125-003-1090-z Mohlig, 2004, The polycystic ovary syndrome per se is not associated with increased chronic inflammation, Eur J Endocrinol, 150, 525, 10.1530/eje.0.1500525 Cresswell, 1997, Fetal growth, length of gestation, and polycystic ovaries in adult life, Lancet, 350, 1131, 10.1016/S0140-6736(97)06062-5 Gambineri, 2002, Obesity and the polycystic ovary syndrome, Int J Obes Relat Metab Disord, 26, 883, 10.1038/sj.ijo.0801994 Carmina, 1992, Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome?, Am J Obstet Gynecol, 167, 1807, 10.1016/0002-9378(92)91779-A Kasim-Karakas, 2004, Metabolic and endocrine effects of a polyunsaturated fatty acid-rich diet in polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 615, 10.1210/jc.2003-030666 Asunción, 2000, A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain, J Clin Endocrinol Metab, 85, 2434, 10.1210/jc.85.7.2434 Azziz, 2004, The prevalence and features of the polycystic ovary syndrome in an unselected population, J Clin Endocrinol Metab, 89, 2745, 10.1210/jc.2003-032046 Diamanti-Kandarakis, 1999, A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile, J Clin Endocrinol Metab, 84, 4006, 10.1210/jc.84.11.4006 Fernandez-Real, 1999, Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness, Diabetologia, 42, 1367, 10.1007/s001250051451 Eaton, 1985, Paleolithic nutrition. A consideration of its nature and current implications, N Engl J Med, 312, 283, 10.1056/NEJM198501313120505 Parsons, 1997, Success in mating: a coordinated approach to fitness through genotypes incorporating genes for stress resistance and heterozygous advantage under stress, Behav Genet, 27, 75, 10.1023/A:1025619510292 Burghen, 1980, Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease, J Clin Endocrinol Metab, 50, 113, 10.1210/jcem-50-1-113 Shoupe, 1983, Insulin resistance in polycystic ovary syndrome, Am J Obstet Gynecol, 147, 588, 10.1016/0002-9378(83)90023-6 Chang, 1983, Insulin resistance in nonobese patients with polycystic ovarian disease, J Clin Endocrinol Metab, 57, 356, 10.1210/jcem-57-2-356 Dunaif, 1989, Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome, Diabetes, 38, 1165, 10.2337/diabetes.38.9.1165 Rajkhowa, 1994, Insulin sensitivity in women with polycystic ovary syndrome: relationship to hyperandrogenemia, Fertil Steril, 61, 605, 10.1016/S0015-0282(16)56633-3 Adashi, 1981, Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells, Endocrinology, 108, 1441, 10.1210/endo-108-4-1441 Moghetti, 1996, Insulin infusion amplifies 17-alpha-hydroxycorticosteroid intermediates response to adrenocorticotropin in hyperandrogenic women—apparent relative impairment of 17,20-lyase activity, J Clin Endocrinol Metab, 81, 881, 10.1210/jc.81.3.881 Poretsky, 1999, The insulin-related ovarian regulatory system in health and disease, Endocr Rev, 20, 535, 10.1210/er.20.4.535 Nestler, 1996, Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome, N Engl J Med, 335, 617, 10.1056/NEJM199608293350902 Nestler, 1993, Sex hormone-binding globulin: a marker for hyperinsulinemia and/or insulin resistance?, J Clin Endocrinol Metab, 76, 273, 10.1210/jc.76.2.273 Nestler, 1997, Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications, Semin Reprod Endocrinol, 15, 111, 10.1055/s-2007-1016294 Wilroy, 1975, Hyperthecosis: an inheritable form of polycystic ovarian disease, Birth Defects Orig Artic Ser, 11, 81 Givens, 1971, Ovarian hyperthecosis, N Engl J Med, 285, 691, 10.1056/NEJM197109162851221 Sam, 2005, Dyslipidemia and metabolic syndrome in the sisters of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4797, 10.1210/jc.2004-2217 Ehrmann, 1995, Insulin secretory defects in polycystic ovary syndrome. Relationship to insulin sensitivity and family history of non-insulin-dependent diabetes mellitus, J Clin Invest, 96, 520, 10.1172/JCI118064 Colilla, 2001, Heritability of insulin secretion and insulin action in women with polycystic ovary syndrome and their first degree relatives, J Clin Endocrinol Metab, 86, 2027, 10.1210/jc.86.5.2027 Lucassen, 1993, Susceptibility to insulin dependent diabetes mellitus maps to a 4.1 kb segment of DNA spanning the insulin gene and associated VNTR, Nat Genet, 4, 305, 10.1038/ng0793-305 Bell, 1982, The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences, Nature, 295, 31, 10.1038/295031a0 Waterworth, 1997, Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome, Lancet, 349, 986, 10.1016/S0140-6736(96)08368-7 Michelmore, 2001, Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight, Clin Endocrinol (Oxf), 55, 439, 10.1046/j.1365-2265.2001.01375.x Calvo, 2002, Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women, Fertil Steril, 77, 666, 10.1016/S0015-0282(01)03238-1 Vankova, 2002, Association of insulin gene VNTR polymorphism with polycystic ovary syndrome, Ann N Y Acad Sci, 967, 558, 10.1111/j.1749-6632.2002.tb04317.x Powell, 2005, Analysis of multiple data sets reveals no association between the insulin gene variable number tandem repeat element and polycystic ovary syndrome or related traits, J Clin Endocrinol Metab, 90, 2988, 10.1210/jc.2004-2485 Dunaif, 1995, Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle. A potential mechanism for insulin resistance in the polycystic ovary syndrome, J Clin Invest, 96, 801, 10.1172/JCI118126 Li, 2002, Decreased insulin receptor (IR) autophosphorylation in fibroblasts from patients with PCOS: effects of serine kinase inhibitors and IR activators, J Clin Endocrinol Metab, 87, 4088, 10.1210/jc.2002-020363 Conway, 1994, The tyrosine kinase domain of the insulin receptor gene is normal in women with hyperinsulinaemia and polycystic ovary syndrome, Hum Reprod, 9, 1681, 10.1093/oxfordjournals.humrep.a138773 Siegel, 2002, A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome, Fertil Steril, 78, 1240, 10.1016/S0015-0282(02)04241-3 Chen, 2004, Correlation between single nucleotide polymorphism of insulin receptor gene with polycystic ovary syndrome, Zhonghua Fu Chan Ke Za Zhi, 39, 582 Urbanek, 1999, Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin, Proc Natl Acad Sci U S A, 96, 8573, 10.1073/pnas.96.15.8573 M. Urbanek, A. Woodroffe, K.G., Ewens, et al. Candidate gene region for polycystic ovary syndrome (PCOS) on chromosome 19p13.2. J Clin Endocrinol Metab 2005 [First published August 9 as doi:10.1210/jc.2005–0622]. Tucci, 2001, Evidence for association of polycystic ovary syndrome in Caucasian women with a marker at the insulin receptor gene locus, J Clin Endocrinol Metab, 86, 446, 10.1210/jc.86.1.446 Villuendas, 2003, Association between the D19S884 marker at the insulin receptor gene locus and polycystic ovary syndrome, Fertil Steril, 79, 219, 10.1016/S0015-0282(02)04570-3 Sorbara, 1994, Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome, Metabolism, 43, 1568, 10.1016/0026-0495(94)90018-3 Talbot, 1996, Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome, J Clin Endocrinol Metab, 81, 1979, 10.1210/jc.81.5.1979 Corbould, 2005, 288, E1047 Sir-Petermann, 2001, G972R polymorphism of IRS-1 in women with polycystic ovary syndrome, Diabetologia, 44, 1200, 10.1007/s001250170001 El Mkadem, 2001, Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate-to-severe insulin resistance of women with polycystic ovary syndrome, Diabetes, 50, 2164, 10.2337/diabetes.50.9.2164 Ehrmann, 2002, Relationship of insulin receptor substrate-1 and-2 genotypes to phenotypic features of polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 4297, 10.1210/jc.2002-020216 Villuendas, 2005, Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls, Hum Reprod, 20, 3184, 10.1093/humrep/dei205 San Millan, 2004, Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity, J Clin Endocrinol Metab, 89, 2640, 10.1210/jc.2003-031252 Witchel, 2001, Inconsistent effects of the proline12->alanine variant of the peroxisome proliferator-activated receptor-gamma2 gene on body mass index in children and adolescent girls, Fertil Steril, 76, 741, 10.1016/S0015-0282(01)01982-3 Hara, 2002, Insulin resistance is attenuated in women with polycystic ovary syndrome with the Pro(12)Ala polymorphism in the PPARgamma gene, J Clin Endocrinol Metab, 87, 772, 10.1210/jc.87.2.772 Korhonen, 2003, Polymorphism in the peroxisome proliferator-activated receptor-gamma gene in women with polycystic ovary syndrome, Hum Reprod, 18, 540, 10.1093/humrep/deg128 Tok, 2005, Evaluation of glucose metabolism and reproductive hormones in polycystic ovary syndrome on the basis of peroxisome proliferator-activated receptor (PPAR)-gamma2 Pro12Ala genotype, Hum Reprod, 20, 1590, 10.1093/humrep/deh769 Hahn, 2005, The peroxisome proliferator activated receptor gamma Pro12Ala polymorphism is associated with a lower hirsutism score and increased insulin sensitivity in women with polycystic ovary syndrome, Clin Endocrinol (Oxf), 62, 573, 10.1111/j.1365-2265.2005.02261.x Ehrmann, 2002, Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 1669, 10.1210/jc.87.4.1669 Escobar-Morreale, 2002, Common single nucleotide polymorphisms in intron 3 of the calpain-10 gene influence hirsutism, Fertil Steril, 77, 581, 10.1016/S0015-0282(01)03206-X Gonzalez, 2002, Comment: CAPN10 alleles are associated with polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 3971, 10.1210/jc.87.8.3971 Gonzalez, 2003, Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients, J Clin Endocrinol Metab, 88, 5529, 10.1210/jc.2003-030322 Panidis, 2004, Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Delta4-androstenedione, Hum Reprod, 19, 1728, 10.1093/humrep/deh336 Xita, 2005, Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome, Clin Chem, 51, 416, 10.1373/clinchem.2004.043109 Orio, 2003, Exon 6 and 2 peroxisome proliferator-activated receptor-gamma polymorphisms in polycystic ovary syndrome, J Clin Endocrinol Metab, 88, 5887, 10.1210/jc.2002-021816 Orio, 2004, Lack of an association between peroxisome proliferator-activated receptor-gamma gene Pro12Ala polymorphism and adiponectin levels in the polycystic ovary syndrome, J Clin Endocrinol Metab, 89, 5110, 10.1210/jc.2004-0109 Witchel, 2003, Frequency of the T228A polymorphism in the SORBS1 gene in children with premature pubarche and in adolescent girls with hyperandrogenism, Fertil Steril, 80, 128, 10.1016/S0015-0282(03)00506-5 Haddad, 2002, Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 2606, 10.1210/jc.87.6.2606 Kumar, 2005, Prevalence of adrenal androgen excess in patients with the polycystic ovary syndrome (PCOS), Clin Endocrinol (Oxf), 62, 644, 10.1111/j.1365-2265.2005.02256.x Carey, 1993, Evidence for a single gene effect causing polycystic ovaries and male pattern baldness, Clin Endocrinol (Oxf), 38, 653, 10.1111/j.1365-2265.1993.tb02150.x Duskova, 2004, What may be the markers of the male equivalent of polycystic ovary syndrome?, Physiol Res, 53, 287, 10.33549/physiolres.930573 Legro, 2002, Elevated dehydroepiandrosterone sulfate levels as the reproductive phenotype in the brothers of women with polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 2134, 10.1210/jc.87.5.2134 Ehrmann, 1995, Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to dysregulation of androgen secretion, Endocr Rev, 16, 322, 10.1210/er.16.3.322 Haavisto, 1995, Occurrence and biological properties of a common genetic variant of luteinizing hormone, J Clin Endocrinol Metab, 80, 1257, 10.1210/jc.80.4.1257 Tapanainen, 1999, A new contributing factor to polycystic ovary syndrome: the genetic variant of luteinizing hormone, J Clin Endocrinol Metab, 84, 1711, 10.1210/jc.84.5.1711 Elter, 1999, Role of the mutations Trp8=>Arg and Ile15=>Thr of the human luteinizing hormone beta-subunit in women with polycystic ovary syndrome, Fertil Steril, 71, 425, 10.1016/S0015-0282(98)00491-9 Takahashi, 2003, Influence of missense mutation and silent mutation of LHbeta-subunit gene in Japanese patients with ovulatory disorders, Eur J Hum Genet, 11, 402, 10.1038/sj.ejhg.5200968 Liao, 1998, A new molecular variant of luteinizing hormone associated with female infertility, Fertil Steril, 69, 102, 10.1016/S0015-0282(97)00445-7 Tong, 2000, Association of AccI polymorphism in the follicle-stimulating hormone beta gene with polycystic ovary syndrome, Fertil Steril, 74, 1233, 10.1016/S0015-0282(00)01616-2 Tong, 2001, Absence of mutations in the coding regions of follicle-stimulating hormone receptor gene in Singapore Chinese women with premature ovarian failure and polycystic ovary syndrome, Horm Metab Res, 33, 221, 10.1055/s-2001-14941 Nelson, 1999, Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries, Mol Endocrinol, 13, 946, 10.1210/me.13.6.946 Nelson, 2001, The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome, J Clin Endocrinol Metab, 86, 5925, 10.1210/jc.86.12.5925 Wickenheisser, 2000, Differential activity of the cytochrome P450 17alpha-hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells, J Clin Endocrinol Metab, 85, 2304, 10.1210/jc.85.6.2304 Wickenheisser, 2005, Dysregulation of cytochrome P450 17alpha-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 1720, 10.1210/jc.2004-1860 Nelson-Degrave, 2005, Alterations in mitogen-activated protein kinase kinase and extracellular regulated kinase signaling in theca cells contribute to excessive androgen production in polycystic ovary syndrome, Mol Endocrinol, 19, 379, 10.1210/me.2004-0178 Wickenheisser, 2004, Increased cytochrome P450 17alpha-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1, Mol Endocrinol, 18, 588, 10.1210/me.2003-0090 Wickenheisser, 2005, Retinoids and retinol differentially regulate steroid biosynthesis in ovarian theca cells isolated from normal cycling women and women with polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4858, 10.1210/jc.2005-0330 Wood, 2004, The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling, J Reprod Immunol, 63, 51, 10.1016/j.jri.2004.01.010 Zhang, 1995, Serine phosphorylation of human P450c17 increases 17,20-lyase activity: implications for adrenarche and the polycystic ovary syndrome, Proc Natl Acad Sci U S A, 92, 10619, 10.1073/pnas.92.23.10619 Qin, 1998, Role of cytochrome P450c17 in polycystic ovary syndrome, Mol Cell Endocrinol, 145, 111, 10.1016/S0303-7207(98)00177-4 Martens, 2000, Enzymatic activities of P450c17 stably expressed in fibroblasts from patients with the polycystic ovary syndrome, J Clin Endocrinol Metab, 85, 4338, 10.1210/jc.85.11.4338 Carey, 1994, Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17, Hum Mol Genet, 3, 1873, 10.1093/hmg/3.10.1873 Diamanti-Kandarakis, 1999, Polymorphism T⤍C (−34 bp) of gene CYP17 promoter in Greek patients with polycystic ovary syndrome, Fertil Steril, 71, 431, 10.1016/S0015-0282(98)00512-3 Franks, 1997, The 17 alpha-hydroxylase/17,20 lyase gene (CYP17) and polycystic ovary syndrome, Clin Endocrinol (Oxf), 46, 135, 10.1046/j.1365-2265.1997.1450937.x Franks, 1996, Hypersecretion of androgens by polycystic ovaries: the role of genetic factors in the regulation of cytochrome P450c17 alpha, Baillieres Clin Endocrinol Metab, 10, 193, 10.1016/S0950-351X(96)80057-7 Liovic, 1997, CYP17 gene analysis in hyperandrogenised women with and without exaggerated 17-hydroxyprogesterone response to ovarian stimulation, J Endocrinol Invest, 20, 189, 10.1007/BF03346901 Marszalek, 2001, Investigations on the genetic polymorphism in the region of CYP17 gene encoding 5′-UTR in patients with polycystic ovarian syndrome, Gynecol Endocrinol, 15, 123 Techatraisk, 1997, Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase (CYP17) gene in hyperandrogenic states, Clin Endocrinol, 46, 131, 10.1046/j.1365-2265.1997.8700880.x Witchel, 1998, 17 alpha-hydroxylase/17,20-lyase dysregulation is not caused by mutations in the coding regions of CYP17, J Pediatr Adolesc Gynecol, 11, 133, 10.1016/S1083-3188(98)70132-9 Gharani, 1997, Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism, Hum Mol Genet, 6, 397, 10.1093/hmg/6.3.397 Diamanti-Kandarakis, 2000, Microsatellite polymorphism (tttta) at-528 base pairs of gene CYP11a influences hyperandrogenemia in patients with polycystic ovary syndrome, Fertil Steril, 73, 735, 10.1016/S0015-0282(99)00628-7 Daneshmand, 2002, Overexpression of theca-cell messenger RNA in polycystic ovary syndrome does not correlate with polymorphisms in the cholesterol side-chain cleavage and 17alpha-hydroxylase/C(17–20) lyase promoters, Fertil Steril, 77, 274, 10.1016/S0015-0282(01)02999-5 San Millán, 2001, Role of the pentanucleotide (tttta)n polymorphism in the promoter of the CYP11a gene in the pathogenesis of hirsutism, Fertil Steril, 75, 797, 10.1016/S0015-0282(01)01677-6 Calvo, 2001, Screening for mutations in the steroidogenic acute regulatory protein and steroidogenic factor-1 genes, and in CYP11A and dosage-sensitive sex reversal-adrenal hypoplasia gene on the X chromosome, gene-1 (DAX-1), in hyperandrogenic hirsute women, J Clin Endocrinol Metab, 86, 1746, 10.1210/jc.86.4.1746 Siegel, 1990, ACTH stimulation tests and plasma dehydroepiandrosterone sulfate levels in women with hirsutism, N Engl J Med, 323, 849, 10.1056/NEJM199009273231301 Eldar Geva, 1990, Secondary biosynthetic defects in women with late-onset congenital adrenal hyperplasia, N Engl J Med, 323, 855, 10.1056/NEJM199009273231302 Chang, 1995, Absence of molecular defect in the type II 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD) gene in premature pubarche children and hirsute female patients with moderately decreased adrenal 3 beta-HSD activity, Pediatr Res, 37, 820, 10.1203/00006450-199506000-00024 Escobar-Morreale, 1999, The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotype–genotype correlations, Fertil Steril, 72, 629, 10.1016/S0015-0282(99)00317-9 Carbunaru, 2004, The hormonal phenotype of nonclassic 3β-hydroxysteroid dehydrogenase (HSD3B) deficiency in hyperandrogenic females is associated with insulin-resistant polycystic ovary syndrome and is not a variant of inherited HSD3B2 deficiency, J Clin Endocrinol Metab, 89, 783, 10.1210/jc.2003-030934 Moghrabi, 1998, Deleterious missense mutations and silent polymorphism in the human 17beta-hydroxysteroid dehydrogenase 3 gene (HSD17B3), J Clin Endocrinol Metab, 83, 2855, 10.1210/jc.83.8.2855 Tomlinson, 2004, 11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response, Endocr Rev, 25, 831, 10.1210/er.2003-0031 Draper, 2003, Mutations in the genes encoding 11beta-hydroxysteroid dehydrogenase type 1 and hexose-6-phosphate dehydrogenase interact to cause cortisone reductase deficiency, Nat Genet, 34, 434, 10.1038/ng1214 San Millan, 2005, A study of the hexose-6-phosphate dehydrogenase gene R453Q and 11beta-hydroxysteroid dehydrogenase type 1 gene 83557insA polymorphisms in the polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 4157, 10.1210/jc.2004-1523 White, 2005, Genotypes at HSD11B1 and H6PD loci are not risk factors for apparent cortisone reductase deficiency in a large population-based sample, J Clin Endocrinol Metab, 90, 5880, 10.1210/jc.2005-0942 Hogeveen, 2002, Human sex hormone-binding globulin variants associated with hyperandrogenism and ovarian dysfunction, J Clin Invest, 109, 973, 10.1172/JCI0214060 Xita, 2003, Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels, J Clin Endocrinol Metab, 88, 5976, 10.1210/jc.2003-030197 Cousin, 2004, Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women, J Clin Endocrinol Metab, 89, 917, 10.1210/jc.2002-021553 Xita, 2005, Association of SHBG gene polymorphism with menarche, Mol Hum Reprod, 11, 459, 10.1093/molehr/gah178 Jakimiuk, 1999, 5alpha-reductase activity in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 84, 2414, 10.1210/jc.84.7.2414 Carson-Jurica, 1990, Steroid receptor family: structure and functions, Endocr Rev, 11, 201, 10.1210/edrv-11-2-201 Legro, 1994, Size polymorphisms of the androgen receptor among female Hispanics and correlation with androgenic characteristics, Obstet Gynecol, 83, 701 Ibanez, 2003, Androgen receptor gene CAG repeat polymorphism in the development of ovarian hyperandrogenism, J Clin Endocrinol Metab, 88, 3333, 10.1210/jc.2002-021791 Vottero, 1999, Androgen receptor-mediated hypersensitivity to androgens in women with nonhyperandrogenic hirsutism: skewing of X-chromosome inactivation, J Clin Endocrinol Metab, 84, 1091, 10.1210/jc.84.3.1091 Hickey, 2002, The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome, J Clin Endocrinol Metab, 87, 161, 10.1210/jc.87.1.161 Calvo, 2000, The role of the CAG repeat polymorphism in the androgen-receptor gene and of skewed X-chromosome inactivation, in the pathogenesis of hirsutism, J Clin Endocrinol Metab, 85, 1735, 10.1210/jc.85.4.1735 Ross, 1999, Atherosclerosis—an inflammatory disease, N Engl J Med, 340, 115, 10.1056/NEJM199901143400207 Howard, 1996, Insulin sensitivity and atherosclerosis. The Insulin Resistance Atherosclerosis Study (IRAS) Investigators, Circulation, 93, 1809, 10.1161/01.CIR.93.10.1809 Ridker, 2000, C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women, N Engl J Med, 342, 836, 10.1056/NEJM200003233421202 Ridker, 2001, Role of inflammatory biomarkers in prediction of coronary heart disease, Lancet, 358, 946, 10.1016/S0140-6736(01)06112-8 Hotamisligil, 1999, The role of TNFalpha and TNF receptors in obesity and insulin resistance, J Intern Med, 245, 621, 10.1046/j.1365-2796.1999.00490.x Legro, 2003, Polycystic ovary syndrome and cardiovascular disease: a premature association?, Endocr Rev, 24, 302, 10.1210/er.2003-0004 Orio, 2005, The increase of leukocytes as a new putative marker of low-grade chronic inflammation and early cardiovascular risk in polycystic ovary syndrome, J Clin Endocrinol Metab, 90, 2, 10.1210/jc.2004-0628 Ibanez, 2005, High neutrophil count in girls and women with hyperinsulinaemic hyperandrogenism: normalization with metformin and flutamide overcomes the aggravation by oral contraception, Hum Reprod, 20, 2457, 10.1093/humrep/dei072 Escobar-Morreale, 2004, Serum interleukin-18 concentrations are increased in the polycystic ovary syndrome: relationship to insulin resistance and to obesity, J Clin Endocrinol Metab, 89, 806, 10.1210/jc.2003-031365 Loverro, 2002, The plasma homocysteine levels are increased in polycystic ovary syndrome, Gynecol Obstet Invest, 53, 157, 10.1159/000058367 Escobar-Morreale, 2005, Body iron stores are increased in overweight and obese women with polycystic ovary syndrome, Diabetes Care, 28, 2042, 10.2337/diacare.28.8.2042 Hotamisligil, 1996, IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance, Science, 271, 665, 10.1126/science.271.5249.665 Roby, 1990, Effects of tumor necrosis factor-alpha in vitro on steroidogenesis of healthy and atretic follicles of the rat: theca as a target, Endocrinology, 126, 2711, 10.1210/endo-126-5-2711 Spaczynski, 1999, Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells, Biol Reprod, 61, 993, 10.1095/biolreprod61.4.993 Kaipia, 1996, Tumor necrosis factor-alpha and its second messenger, ceramide, stimulate apoptosis in cultured ovarian follicles, Endocrinology, 137, 4864, 10.1210/en.137.11.4864 Gonzalez, 1999, Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome, Metabolism, 48, 437, 10.1016/S0026-0495(99)90100-2 Milner, 1999, No association between the−308 polymorphism in the tumour necrosis factor alpha (TNFalpha) promoter region and polycystic ovaries, Mol Hum Reprod, 5, 5, 10.1093/molehr/5.1.5 Korhonen, 2002, Lack of association between C-850T polymorphism of the gene encoding tumor necrosis factor-alpha and polycystic ovary syndrome, Gynecol Endocrinol, 16, 271, 10.1080/713603095 Uysal, 1998, Functional analysis of tumor necrosis factor (TNF) receptors in TNF-alpha-mediated insulin resistance in genetic obesity, Endocrinology, 139, 4832, 10.1210/en.139.12.4832 Bazzoni, 1996, The tumor necrosis factor ligand and receptor families, N Engl J Med, 334, 1717, 10.1056/NEJM199606273342607 Fernandez-Real, 1998, Plasma levels of the soluble fraction of tumor necrosis factor receptor 2 and insulin resistance, Diabetes, 47, 1757, 10.2337/diabetes.47.11.1757 Fernandez-Real, 1999, Tumor necrosis factor system activity is associated with insulin resistance and dyslipidemia in myotonic dystrophy, Diabetes, 48, 1108, 10.2337/diabetes.48.5.1108 Papanicolaou, 2000, Interleukin-6: the endocrine cytokine, J Clin Endocrinol Metab, 85, 1331, 10.1210/jc.85.3.1331 Haan, 2002, Structural requirements of the interleukin-6 signal transducer gp130 for its interaction with Janus kinase 1: the receptor is crucial for kinase activation, Biochem J, 361, 105, 10.1042/0264-6021:3610105 Walch, 2004, A common interleukin-6 gene promoter polymorphism influences the clinical characteristics of women with polycystic ovary syndrome, Fertil Steril, 81, 1638, 10.1016/j.fertnstert.2004.01.021 Yildiz, 2002, Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state, J Clin Endocrinol Metab, 87, 3871, 10.1210/jc.87.8.3871 Tsanadis, 2002, Polycystic ovarian syndrome and thrombophilia, Hum Reprod, 17, 314, 10.1093/humrep/17.2.314 Glueck, 2000, Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage, Fertil Steril, 74, 394, 10.1016/S0015-0282(00)00630-0 Sobel, 1999, Insulin resistance and thrombosis: a cardiologist's view, Am J Cardiol, 84, 37J, 10.1016/S0002-9149(99)00357-4 Sakamoto, 1999, TNF-alpha and insulin, alone and synergistically, induce plasminogen activator inhibitor-1 expression in adipocytes, Am J Physiol, 276, C1391, 10.1152/ajpcell.1999.276.6.C1391 Velazquez, 1997, Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome, Metabolism, 46, 454, 10.1016/S0026-0495(97)90066-4 Glueck, 1999, Plasminogen activator inhibitor activity: an independent risk factor for the high miscarriage rate during pregnancy in women with polycystic ovary syndrome, Metabolism, 48, 1589, 10.1016/S0026-0495(99)90250-0 Ehrmann, 1997, Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome, J Clin Endocrinol Metab, 82, 2108, 10.1210/jc.82.7.2108 Atiomo, 2000, Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS), Clin Endocrinol (Oxf), 52, 487, 10.1046/j.1365-2265.2000.00946.x McCormack, 1996, Promoter (4G/5G) plasminogen activator inhibitor-1 genotype in Pima Indians: relationship to plasminogen activator inhibitor-1 levels and features of the insulin resistance syndrome, Diabetologia, 39, 1512, 10.1007/s001250050606 Diamanti-Kandarakis, 2004, The prevalence of 4G5G polymorphism of plasminogen activator inhibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels, Eur J Endocrinol, 150, 793, 10.1530/eje.0.1500793 Walch, 2005, A polymorphism of the plasminogen activator inhibitor-1 gene promoter and the polycystic ovary syndrome, Eur J Obstet Gynecol Reprod Biol, 123, 77, 10.1016/j.ejogrb.2005.07.002 Baker, 2002, Gonadotropin secretory dynamics in polycystic ovary syndrome, Curr Opin Endocrinol Diabetes, 9, 475, 10.1097/00060793-200212000-00006